Literature DB >> 25836667

Reprogramming Mouse Cells With a Pancreatic Duct Phenotype to Insulin-Producing β-Like Cells.

Takatsugu Yamada1, Claudia Cavelti-Weder, Francisco Caballero, Philippe A Lysy, Lili Guo, Arun Sharma, Weida Li, Qiao Zhou, Susan Bonner-Weir, Gordon C Weir.   

Abstract

Reprogramming technology has opened the possibility of converting one cell type into another by forced expression of transgenes. Transduction of adenoviral vectors encoding 3 pancreatic transcription factors, Pdx1, Ngn3, and MafA, into mouse pancreas results in direct reprogramming of exocrine cells to insulin-producing β-like cells. We hypothesized that cultured adult pancreatic duct cells could be reprogrammed to become insulin-producing β-cells by adenoviral-mediated expression of this same combination of factors. Exocrine were isolated from adult mouse insulin 1 promoter (MIP)-green fluorescent protein (GFP) transgenic mice to allow new insulin-expressing cells to be detected by GFP fluorescence. Cultured cells were transduced by an adenoviral vector carrying a polycistronic construct Ngn3/Pdx1/MafA/mCherry (Ad-M3C) or mCherry sequence alone as a control vector. In addition, the effects of glucagon-like peptide-1 (GLP-1) receptor agonist, exendin-4 (Ex-4) on the reprogramming process were examined. GFP(+) cells appeared 2 days after Ad-M3C transduction; the reprogramming efficiency was 8.6 ± 2.6% by day 4 after transduction. Ad-M3C also resulted in increased expression of β-cell markers insulin 1 and 2, with enhancement by Ex-4. Expression of other β-cell markers, neuroD and GLP-1 receptor, were also significantly up-regulated. The amount of insulin release into the media and insulin content of the cells were significantly higher in the Ad-M3C-transduced cells; this too was enhanced by Ex-4. The transduced cells did not secrete insulin in response to increased glucose, indicating incomplete differentiation to β-cells. Thus, cultured murine adult pancreatic cells with a duct phenotype can be directly reprogrammed to insulin-producing β-like cells by adenoviral delivery of 3 pancreatic transcription factors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25836667      PMCID: PMC4430605          DOI: 10.1210/en.2014-1987

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  40 in total

1.  Efficient differentiation of AR42J cells towards insulin-producing cells using pancreatic transcription factors in combination with growth factors.

Authors:  Maria João Lima; Hilary M Docherty; Yuanxiao Chen; Kevin Docherty
Journal:  Mol Cell Endocrinol       Date:  2012-03-10       Impact factor: 4.102

Review 2.  Pharmacology, physiology, and mechanisms of incretin hormone action.

Authors:  Jonathan E Campbell; Daniel J Drucker
Journal:  Cell Metab       Date:  2013-05-16       Impact factor: 27.287

Review 3.  Control of cell identity in pancreas development and regeneration.

Authors:  Ben Z Stanger; Matthias Hebrok
Journal:  Gastroenterology       Date:  2013-06       Impact factor: 22.682

4.  Adult pancreatic acinar cells dedifferentiate to an embryonic progenitor phenotype with concomitant activation of a senescence programme that is present in chronic pancreatitis.

Authors:  Andreia V Pinho; Ilse Rooman; Maximilian Reichert; Nele De Medts; Luc Bouwens; Anil K Rustgi; Francisco X Real
Journal:  Gut       Date:  2010-12-30       Impact factor: 23.059

5.  Differentiation of affinity-purified human pancreatic duct cells to beta-cells.

Authors:  Shigeru Yatoh; Rikke Dodge; Tomoyuki Akashi; Abdulkadir Omer; Arun Sharma; Gordon C Weir; Susan Bonner-Weir
Journal:  Diabetes       Date:  2007-05-01       Impact factor: 9.461

Review 6.  How to make a functional β-cell.

Authors:  Felicia W Pagliuca; Douglas A Melton
Journal:  Development       Date:  2013-06       Impact factor: 6.868

7.  Generation of islet-like cells from mouse gall bladder by direct ex vivo reprogramming.

Authors:  Raymond D Hickey; Feorillo Galivo; Jonathan Schug; Michael A Brehm; Annelise Haft; Yuhan Wang; Eric Benedetti; Guoqiang Gu; Mark A Magnuson; Leonard D Shultz; Eric Lagasse; Dale L Greiner; Klaus H Kaestner; Markus Grompe
Journal:  Stem Cell Res       Date:  2013-02-18       Impact factor: 2.020

8.  Maturation of human embryonic stem cell-derived pancreatic progenitors into functional islets capable of treating pre-existing diabetes in mice.

Authors:  Alireza Rezania; Jennifer E Bruin; Michael J Riedel; Majid Mojibian; Ali Asadi; Jean Xu; Rebecca Gauvin; Kavitha Narayan; Francis Karanu; John J O'Neil; Ziliang Ao; Garth L Warnock; Timothy J Kieffer
Journal:  Diabetes       Date:  2012-06-27       Impact factor: 9.337

9.  Reprogramming of pancreatic exocrine cells towards a beta (β) cell character using Pdx1, Ngn3 and MafA.

Authors:  Ersin Akinci; Anannya Banga; Lucas V Greder; James R Dutton; Jonathan M W Slack
Journal:  Biochem J       Date:  2012-03-15       Impact factor: 3.857

Review 10.  Islet β cell mass in diabetes and how it relates to function, birth, and death.

Authors:  Gordon C Weir; Susan Bonner-Weir
Journal:  Ann N Y Acad Sci       Date:  2013-01-30       Impact factor: 5.691

View more
  14 in total

1.  V-Maf Musculoaponeurotic Fibrosarcoma Oncogene Homolog A Synthetic Modified mRNA Drives Reprogramming of Human Pancreatic Duct-Derived Cells Into Insulin-Secreting Cells.

Authors:  Elisa Corritore; Yong-Syu Lee; Valentina Pasquale; Daniela Liberati; Mei-Ju Hsu; Catherine Anne Lombard; Patrick Van Der Smissen; Amedeo Vetere; Susan Bonner-Weir; Lorenzo Piemonti; Etienne Sokal; Philippe A Lysy
Journal:  Stem Cells Transl Med       Date:  2016-07-12       Impact factor: 6.940

2.  Exendin-4 promotes the osteogenic differentiation of osteoblasts via the Hedgehog/Gli1 signaling pathway.

Authors:  Liu Gao; Shilun Li; Yukun Li
Journal:  Am J Transl Res       Date:  2018-01-15       Impact factor: 4.060

Review 3.  New Insights into Diabetes Cell Therapy.

Authors:  Philippe A Lysy; Elisa Corritore; Etienne M Sokal
Journal:  Curr Diab Rep       Date:  2016-05       Impact factor: 4.810

Review 4.  Regenerative medicine and cell-based approaches to restore pancreatic function.

Authors:  Cara Ellis; Adam Ramzy; Timothy J Kieffer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-08-16       Impact factor: 46.802

5.  Growth factors and medium hyperglycemia induce Sox9+ ductal cell differentiation into β cells in mice with reversal of diabetes.

Authors:  Mingfeng Zhang; Qing Lin; Tong Qi; Tiankun Wang; Ching-Cheng Chen; Arthur D Riggs; Defu Zeng
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-05       Impact factor: 11.205

Review 6.  β-cell replacement sources for type 1 diabetes: a focus on pancreatic ductal cells.

Authors:  Elisa Corritore; Yong-Syu Lee; Etienne M Sokal; Philippe A Lysy
Journal:  Ther Adv Endocrinol Metab       Date:  2016-06-06       Impact factor: 3.565

Review 7.  β-Cell Replacement Strategies: The Increasing Need for a "β-Cell Dogma".

Authors:  Andhira Vieira; Noémie Druelle; Fabio Avolio; Tiziana Napolitano; Sergi Navarro-Sanz; Serena Silvano; Patrick Collombat
Journal:  Front Genet       Date:  2017-06-06       Impact factor: 4.599

8.  Tailored generation of insulin producing cells from canine mesenchymal stem cells derived from bone marrow and adipose tissue.

Authors:  Watchareewan Rodprasert; Sirirat Nantavisai; Koranis Pathanachai; Prasit Pavasant; Thanaphum Osathanon; Chenphop Sawangmake
Journal:  Sci Rep       Date:  2021-06-11       Impact factor: 4.379

Review 9.  β-Cell regeneration through the transdifferentiation of pancreatic cells: Pancreatic progenitor cells in the pancreas.

Authors:  Hyo-Sup Kim; Moon-Kyu Lee
Journal:  J Diabetes Investig       Date:  2016-02-29       Impact factor: 4.232

10.  Heterogeneity of SOX9 and HNF1β in Pancreatic Ducts Is Dynamic.

Authors:  Habib Rezanejad; Limor Ouziel-Yahalom; Charlotte A Keyzer; Brooke A Sullivan; Jennifer Hollister-Lock; Wan-Chun Li; Lili Guo; Shaopeng Deng; Ji Lei; James Markmann; Susan Bonner-Weir
Journal:  Stem Cell Reports       Date:  2018-03-01       Impact factor: 7.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.